New combo tackles Hard-to-Treat brain cancer
NCT ID NCT03050736
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This study tested a drug called VAL-083 combined with standard radiation in 29 adults with a newly diagnosed, aggressive brain cancer (glioblastoma) that has a specific genetic marker (unmethylated MGMT). The goal was to find the safest dose and see if the combination shrinks tumors. Participants received the drug and radiation, then were monitored with MRI scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, 510060, China
Conditions
Explore the condition pages connected to this study.